This database contains 524 studies, archived under the term: "alzheimer disease"
Click here to filter this large number of results.
Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants
A formula (formula F) was prepared to counteract oxidative stress (OS) in the brain. The formula contained the most common antioxidants and was intended to: (a) protect proteins, lipids, DNA and proteoglycans from oxidation (carnosine, coenzyme Q(10), vitamin E, vitamin C, beta-carotene, selenium, L-cysteine and ginkgo biloba); (b) reduce homocysteine (HCy) blood levels (vitamins B(6), […]
Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy
Clare, Linda,
Linden, David E. J.,
Woods, Robert T,
Whitaker, Rhiannon,
Evans, Suzannah J.,
Parkinson, Caroline H.,
van Paasschen, Jorien,
Nelis, Sharon M.,
Hoare, Zoe,
Yuen, Kenneth S. L.,
Rugg, Michael D.
Objectives: To provide evidence regarding the clinical efficacy of cognitive rehabilitation (CR) in early-stage Alzheimer disease (AD).; Design: Single-blind randomized controlled trial comparing CR with relaxation therapy and no treatment.; Setting: Outpatient, community-based setting.; Participants: Sixty-nine individuals (41 women, 28 men; mean age 77.78 years, standard deviation 6.32, range = 56-89) with a diagnosis of […]
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative
Carmichael, Owen,
Schwarz, Christopher,
Drucker, David,
Fletcher, Evan,
Harvey, Danielle,
Beckett, Laurel,
Jack, Clifford R., Jr.,
Weiner, Michael,
DeCarli, Charles
Objective: To evaluate relationships between magnetic resonance imaging (MRI)-based measures of white matter hyperintensities (WMHs), measured at baseline and longitudinally, and 1-year cognitive decline using a large convenience sample in a clinical trial design with a relatively mild profile of cardiovascular risk factors.; Design: Convenience sample in a clinical trial design.; Subjects: A total of […]
Transcultural influences in dementia care: observations from a psychosocial intervention study
Burns, Alistair,
Mittelman, Mary,
Cole, Catherine,
Morris, Julie,
Winter, Jane,
Page, Sean,
Brodaty, Henry
Background: Various models of intervention for caregivers of patients with dementia have been described. There has been little direct comparison of cultural differences between countries and the effect any differences may exert on the outcome of caregiver interventions.; Aims: The aims of the three-country study (USA, Australia and the UK) were to assess whether caregiver […]
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer’s disease
Boche, Delphine,
Donald, Jane,
Love, Seth,
Harris, Scott,
Neal, James W.,
Holmes, Clive,
Nicoll, James A. R.
Alzheimer’s disease (AD) pathology is characterised by aggregation in the brain of amyloid-beta (Abeta) peptide and hyperphosphorylated tau (phospho-tau), although how these proteins interact in disease pathogenesis is unclear. Abeta immunisation results in removal of Abeta from the brain but cognitive decline continues to progress, possibly due to persistent phospho-tau. We quantified phospho-tau and Abeta42 […]
A single ascending dose study of bapineuzumab in patients with Alzheimer disease
Black, Ronald S.,
Sperling, Reisa A.,
Safirstein, Beth,
Motter, Ruth N.,
Pallay, Allan,
Nichols, Alice,
Grundman, Michael
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. Thirty patients received bapineuzumab infusion of 0.5, 1.5, or 5 mg/kg or placebo (6 active, 2 placebo for 0.5 […]
3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
Apostolova, Liana G.,
Thompson, Paul M.,
Green, Amity E.,
Hwang, Kristy S.,
Zoumalan, Charleen,
Jack, Clifford R., Jr.,
Harvey, Danielle J.,
Petersen, Ronald C.,
Thal, Leon J.,
Aisen, Paul S,
Toga, Arthur W.,
Cummings, Jeffrey L.,
Decarli, Charles S.
We applied the hippocampal radial atrophy mapping technique to the baseline and follow-up magnetic resonance image data of 169 amnestic mild cognitive impairment (MCI) participants in the imaging arm of the Alzheimer’s Disease Cooperative Study MCI Donepezil/Vitamin E trial. Sixty percent of the subjects with none to mild hippocampal atrophy rated with the visual medial […]
Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study
Zheng, Ling,
Mack, Wendy J.,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Stroup, T. Scott,
Sultzer, David L.,
Tariot, Pierre N.,
Vigen, Cheryl,
Schneider, Lon S.
Objective: The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer’s disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.; Method: The authors assessed 186 male and 235 female Alzheimer’s disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) […]
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study
Wroolie, T. E.,
Kenna, H. A.,
Williams, K. E.,
Powers, B. N.,
Holcomb, M.,
Lazzeroni, L.,
Rasgon, N. L.
Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]